Glenmark has receive final USFDA approval for Solifenacin Succinate Tablets in strengths of 5 mg and 10 mg. The drug Solifenacin Succinate is a generic version of Vesicare Tablets, 5 mg and 10 mg, of Astellas Pharma US.
According to market estimates, sales for the 12 month period ending March 2019, the Vesicare Tablets, 5 mg and 10 mg market is estimated at approximately $942.7 million.
Company Profile : Glenmark Pharma Ltd
Leave a Reply